Takeda (NYSE: TAK) Japan Pharma chief details shares, RSUs and tax awards

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD executive Asuka Miyabashira, President of the Japan Pharma Business Unit, reports direct ownership of 3,000 Ordinary Shares. The position also includes 1,600 restricted stock units (RSUs), which are rights to receive one Ordinary Share each as they vest.

The RSUs vest in tranches of 700 shares on June 1, 2026, 500 shares on June 1, 2027, and 400 shares on June 1, 2028. In addition, Miyabashira holds Tax Obligation Awards that are economically equivalent to Ordinary Shares and are designed to be settled in cash primarily to cover tax obligations at the then-current market price when they vest.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Miyabashira Asuka

(Last) (First) (Middle)

1-1, NIHONBASHI-HONCHO 2-CHOME

CHUO-KU

(Street)

TOKYO 103-8668

(City) (State) (Zip)

JAPAN

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Japan Pharma B.U.

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	3,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Tax Obligation Award	06/01/2026	06/01/2026	Ordinary Shares	1,022	(2)	D
Tax Obligation Award	06/01/2027	06/01/2027	Ordinary Shares	728	(2)	D
Tax Obligation Award	06/01/2028	06/01/2028	Ordinary Shares	510	(2)	D

Explanation of Responses:

1. Includes 1,600 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (700 shares), June 1, 2027 (500 shares) and June 1, 2028 (400 shares).

2. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.

Remarks:

Exhibit 24 Power of Attorney

	/s/ Max Heuer, by power of attorney, for Asuka Miyabashira	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider holdings did Asuka Miyabashira report in Takeda (TAK)?

Asuka Miyabashira reported direct ownership of 3,000 Ordinary Shares of Takeda. The disclosure also notes 1,600 restricted stock units (RSUs) and several Tax Obligation Awards linked to Ordinary Shares, providing a mix of share ownership and equity-based compensation exposure.

How many RSUs does Asuka Miyabashira hold in Takeda (TAK) and how do they vest?

Miyabashira holds 1,600 restricted stock units (RSUs), each linked to one Ordinary Share. These RSUs vest in stages: 700 shares on June 1, 2026, 500 shares on June 1, 2027, and 400 shares on June 1, 2028, subject to the award terms.

What are Tax Obligation Awards reported by Asuka Miyabashira at Takeda (TAK)?

The Tax Obligation Awards are instruments economically equivalent to Ordinary Shares that convert into cash upon vesting. According to the disclosure, the cash payment is intended primarily to cover tax obligations, using the then-current market price of Takeda’s Ordinary Shares as the valuation basis.

How many Ordinary Shares underlie the Tax Obligation Awards for Takeda (TAK)?

Miyabashira’s Tax Obligation Awards reference 1,022 underlying Ordinary Shares expiring June 1, 2026, 728 shares expiring June 1, 2027, and 510 shares expiring June 1, 2028. Each award is described as economically equivalent to one Ordinary Share upon vesting.

What role does Asuka Miyabashira hold at Takeda (TAK) in this ownership report?

In this ownership report, Asuka Miyabashira is identified as an officer of Takeda, serving as President, Japan Pharma Business Unit. The filing ties this leadership role to the detailed disclosure of Ordinary Share holdings, RSUs, and Tax Obligation Awards.